Evidence map›Paper›PMID 35719990›Full record

ArticleFrontiers in oncology2022

Identification of LINC00654-NINL Regulatory Axis in Diffuse Large B-Cell Lymphoma

Yinchu Chen, Chen Li, Nana Wang, Zhenghao Wu, Jin Zhang, Jiawei Yan, Yuanfeng Wei, Qunlong Peng, Jing Qi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Yinchu ChenDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College, WuHu, China.
Chen LiDepartment of Biology, Chemistry, Pharmacy, Free University of Berlin, Berlin, Germany.
Nana WangDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College, WuHu, China.
Zhenghao WuDepartment of Clinical and Surgery, Moscow State First Medical University, Moscow, Russia.
Jin ZhangDepartment of Surgery, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
Jiawei YanDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College, WuHu, China.
Yuanfeng WeiDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College, WuHu, China.
Qunlong PengCollege of Pharmacy, Xiangnan University, Chenzhou, China.
Jing QiDepartment of Hematology, The First Affiliated Hospital of Wannan Medical College, WuHu, China.
First Affiliated Hospital of Wannan Medical College · CNSechenov University · RUFreie Universität Berlin · DEXiangnan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The long non-coding RNA (lncRNA)-mRNA regulation network plays an important role in the development of diffuse large B-cell lymphoma (DLBCL). This study uses bioinformatics to find an innovative regulation axis in DLBCL that will provide a positive reference for defining the mechanism of disease progression. Methods: Batch Cox regression was used to screen prognosis-related lncRNAs, and a random forest model was used to identify hub lncRNA. The clinical value of the lncRNA was evaluated and Spearman correlation analysis was used to predict the candidate target genes. Gene Oncology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment were used to define the biological function of the lncRNA. A batch Cox regression model, expression validation, and Spearman correlation analysis were used to select the best downstream target genes. The expression and prognostic value validation of this gene was conducted using public data. Gene Set Enrichment Analysis (GSEA) was performed to explore potential mechanisms for this gene in DLBCL. Results: LINC00654 was identified as the hub lncRNA and 1443 mRNAs were selected as downstream target genes of the lncRNA. The target genes were enriched in the regulation of GTPase and Notch signaling pathways. After validation, the ninein-like (NINL) gene was selected as the potential target of LINC00654 and the LINC00654-NINL axis was constructed. Patients with better responses to therapy were shown to have high NINL gene expression (p-value = 0.036). NINL also had high expression in the DB cell line and low expression in the OCILY3 cell line. Survival analysis showed that high NINL expression was a risk factor for overall survival (OS) and disease-specific survival (DSS) within older patients and those with advanced-stage cancer. GSEA results showed that NINL may be involved in neutrophil-mediated immunity and NF-κB signaling. Conclusion: This study identified a novel LncRNA00654-NINL regulatory axis in DLBCL, which could provide a favorable reference for exploring the possible mechanisms of disease progression.

Indexed as

DLBCLLINC00654mechnismNINLrandom forest

Identifiers

PMID35719990
PMCPMC9204339
OpenAlexW4281787866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.